PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...
In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Tuesday reported a loss of $29.1 million in its fourth quarter. The San Diego-based company said it had a loss of $1.03 per share. The ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript March 3, 2026 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, ...
Management is transitioning the ARCT-032 cystic fibrosis program into a 12-week Phase II study to better capture clinical healing and efficacy signals beyond the initial 'onboarding' phase. The ...
About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results